Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963880 | 0.94 | MAOA (0.71) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31747379 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL22511877 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL7977069 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1930913 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169526 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL19243360 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1328306 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169524 | 0.93 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL608970 | 0.90 | MAOA (0.60) | MAOAMAOBTDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121022-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | 이화여자대학교 산학협력단 | 2023-06-29 | — | — | WO | claimed |
| CN-102798710-B | Alkaline red G detection kit and preparation method thereof | GUANGZHOU QUALITY SUPERVISION INSPECTION RES INST | 2014-08-27 | — | — | CN | claimed |
| CN-102798710-A | Alkaline red G detection kit and preparation method thereof | GUANGZHOU QUALITY SUPERVISION INSPECTION RES INST | 2012-11-28 | — | — | CN | claimed |
| EP-3794002-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220242905-A1 | MODIFIED PEPTIDES AND THEIR USE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-08-04 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3856758-A1 | MODIFIED PEPTIDES AND THEIR USE | UNIVERSITE DE MONTPELLIER (FR) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021143680-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-3544981-B1 | BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS | ENTERPRISE THERAPEUTICS LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1303528-A1 | ADENOSINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004474-A1 | ADENOSINE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | NIKKEN CHEMICALS CO. LTD. (JP) | 2002-01-17 | — | — | WO | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5397796-A | Inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces | CASSELLA AG (DE) | 1995-03-14 | — | — | US | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | MAOA 1679/4885MAOB 2099/4885TDP1 1200/4885 |
| US-20220242905-A1 | MODIFIED PEPTIDES AND THEIR USE | NGLY1, VIP, NPPA | MAOA 4523/4885MAOB 4554/4885TDP1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.